Washington University Patents UTI Treatment Using Hemolysin Inhibitor
Summary
The USPTO published Washington University's patent application (US20260098073A1) for compositions and methods treating urinary tract infection and sepsis using alpha-hemolysin (HlyA) inhibiting agents. The technology includes soluble LDLR-Fc fusion proteins, clathrin-mediated endocytosis inhibitors, and anti-LDLR antibodies targeting E. coli hemolysin. This grants Washington University exclusive IP rights over these therapeutic compositions.
What changed
The USPTO published Washington University's patent application covering alpha-hemolysin inhibiting agents for treating urinary tract infections and sepsis. The application claims LDLR-Fc fusion proteins with Fc domains and LDLR type A domains, clathrin-mediated endocytosis inhibitors, and anti-LDLR antibodies as therapeutic compositions.
Pharmaceutical companies and healthcare providers developing UTI treatments should monitor this IP position. The patent may restrict research in this therapeutic space or create licensing opportunities for treatments targeting E. coli hemolysin-mediated infections.
What to do next
- Monitor for patent issuance and assess licensing opportunities
- Review composition claims for potential infringement risks
- Evaluate therapeutic applications in UTI treatment pipelines
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR INHIBITION OF E. COLI HEMOLYSIN DURING URINARY TRACT INFECTION
Application US20260098073A1 Kind: A1 Apr 09, 2026
Assignee
Washington University
Inventors
David Hunstad, Hunter Kuhn, Michael Diamond, Hongming Ma
Abstract
Compositions and methods for treating urinary tract infection (UTI) and/or sepsis in a subject in need thereof are provided. Methods include administering to the subject a composition comprising an alpha-hemolysin (HlyA) inhibiting agent. In some embodiments, the HlyA inhibiting agent includes a soluble low-density lipoprotein receptor (LDLR)-Fc fusion protein as described herein, a clathrin-mediated endocytosis (CME) inhibitor, and/or an anti-LDLR antibody. In some embodiments, the soluble LDLR-Fc fusion protein includes an Fc domain and at least one LDLR type A domain. In some embodiments, the UTI and/or sepsis is caused by E. coli.
CPC Classifications
C07K 14/705 A61P 13/02 A61K 38/00 C07K 2319/30
Filing Date
2025-10-04
Application No.
19349990
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.